Δευτέρα 2 Μαΐου 2022

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

alexandrossfakianakis shared this article with you from Inoreader

41408_2022_670_Fig1_HTML.png

Blood Cancer Journal, Published online: 02 May 2022; doi:10.1038/s41408-022-00670-0

Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις